EU15 Minimally Invasive Spinal Implants Market Analysis - COVID19 - 2020-2026 - MedSuite - Includes:
Throughout this medical market research, the publisher analyzed 40+ minimally invasive spinal (MIS) implants companies in Europe and utilized their comprehensive methodology to understand the Market Sizes, Unit Sales, ASPs, Company Market Shares, and to create accurate forecasts.
While this report suite report contains all of the EU15 MIS Implants market analysis, each of the market segments is also available as a stand-alone a report, MedCore.
Markets Covered
MIS Interbody Devices Market - MedCore
MIS Pedicle Screws Market - MedCore
Spinous Process Fixation Devices Market - MedCore
Facet Fixation Devices Market - MedCore
Sacroiliac Joint Fusion Devices Market - MedCore
Spine Endoscopes Market - MedCore
MIS Surgery Instrumentation Market - MedCore
European MIS Implants Market Insights
Overall, the Europe minimally invasive spinal implants market was valued at €144 million in 2020. This is expected to increase over the forecast period to reach €220 million in 2026.
The MIS interbody market continues to see a shift toward OLIF and LLIF devices and away from MIPLIF and MITLIF devices. The oblique and lateral lumbar approaches are expected to see more growth than their posterior and transforaminal lumbar counterparts, although positive growth is expected across segments.
The leading competitor in the European MIS implant market was Medtronic. Medtronic thrives in the MIS pedicle screw market, as a result of its minimal access spine technologies (MAST) systems. These include the Minimal Exposure Tubular Retractor (METRx®) system, the CD Horizon® Sextant™ percutaneous cannulated screw system, the CD Horizon® Legacy™ percutaneous PEEK rod system and the CD Horizon® Longitude®.
Report Regional Coverage
Throughout this research series, the publisher has covered several countries in great detail. The countries covered are:
Germany
France
U.K.
Italy
Spain
Benelux (Belgium, Netherlands, and Luxembourg)
Scandinavia (Denmark, Finland, Norway, and Sweden)
Switzerland
Austria
Portugal
The full report suite on the European market for minimally invasive spinal (MIS) implants includes segments for MIS interbody devices, MIS pedicle screws, spinous process fixation, facet fixation, MIS sacroiliac (SI) joint fusion, spine endoscopes and MIS instrumentation. Growth is expected in many segments, as patient demographics in Europe maintain a steady demand for such procedures.
- EXECUTIVE SUMMARY
- EUROPEAN ORTHOPEDIC BIOMATERIALS MARKET OVERVIEW
- COMPETITIVE ANALYSIS
- MARKET TRENDS
- MARKET DEVELOPMENTS
- PROCEDURE NUMBERS
- MARKETS INCLUDED
- KEY REPORT UPDATES
- VERSION HISTORY
- RESEARCH METHODOLOGY
- Step 1: Project Initiation & Team Selection
- Step 2: Prepare Data Systems and Perform Secondary Research
- Step 3: Preparation for Interviews & Questionnaire Design
- Step 4: Performing Primary Research
- Step 5: Research Analysis: Establishing Baseline Estimates
- Step 6: Market Forecast and Analysis
- Step 7: Identify Strategic Opportunities
- Step 8: Final Review and Market Release
- Step 9: Customer Feedback and Market Monitoring
- IMPACT OF COVID-19 ON THE EUROPEAN ORTHOPEDIC BIOMATERIALS MARKET
- 2.1 INTRODUCTION
- 2.1.1 Treatable Population and the SARS-CoV-2 Virus
- 2.2 ANALYSIS BY MARKET SEGMENT
- 2.2.1 Best Case Scenario
- 2.2.2 Base Case Scenario
- 2.2.3 Worst Case Scenario
- PRODUCT ASSESSMENT
- 3.1 INTRODUCTION
- 3.2 PRODUCT PORTFOLIOS
- 3.2.1 Bone Graft Substitutes
- 3.2.2 Growth Factors
- 3.2.2.1 Other products
- 3.2.3 Cellular Allografts (Stem Cell)
- 3.2.4 Cell Therapy
- 3.2.4.1 Platelet-Rich Plasma
- 3.2.4.2 Concentrated Bone Marrow Aspirate
- 3.2.5 Hyaluronic Acid Viscosupplementation (HAV)
- 3.2.6 Cartilage Repair
- 3.3 REGULATORY ISSUES AND RECALLS
- 3.3.1 Bone Graft Substitutes
- 3.3.1.1 Allografts
- 3.3.1.1.1 MTF
- 3.3.1.2 DBM
- 3.3.1.2.1 AlloSource
- 3.3.1.2.2 SeaSpine
- 3.3.1.2.3 RTI Surgical
- 3.3.1.3 Synthetics
- 3.3.1.3.1 Abyrx
- 3.3.1.3.2 Zimmer Biomet
- 3.3.2 Growth Factors
- 3.3.2.1.1 Medtronic
- 3.3.3 Cell Therapy
- 3.3.3.1 Bone Marrow Cell Therapy
- 3.3.3.1.1 Argon Medical Devices
- 3.3.3.1.2 Stryker
- 3.3.3.1.3 Teleflex
- 3.3.4 Hyaluronic Acid Viscosupplementation
- 3.3.4.1 Three-injection
- 3.3.4.1.1 Ferring Pharmaceuticals
- 3.3.5 Cartilage Repair
- 3.3.5.1.1 Smith & Nephew
- 3.3.5.1.2 Richard Wolf
- 3.4 CLINICAL TRIALS
- EUROPEAN ORTHOPEDIC BIOMATERIALS MARKET OVERVIEW
- 4.1 INTRODUCTION
- 4.1.1 Bone Graft Substitutes
- 4.1.2 Growth Factors
- 4.1.3 Hyaluronic Acid Viscosupplementation
- 4.1.4 Autologous Chondrocyte Implantation
- 4.1.5 Cell Therapies
- 4.2 CURRENCY EXCHANGE RATE
- 4.3 MARKET OVERVIEW
- 4.4 TREND ANALYSIS BY SEGMENT
- 4.5 DRIVERS AND LIMITERS
- 4.5.1 Market Drivers
- 4.5.2 Market Limiters
- 4.6 COMPETITIVE MARKET SHARE ANALYSIS
- 4.7 MERGERS AND ACQUISITIONS
- 4.8 COMPANY PROFILES
- 4.8.1 Anika Therapeutics
- 4.8.2 Bioventus
- 4.8.3 DePuy Synthes
- 4.8.4 Ferring Pharmaceuticals
- 4.8.5 Fidia Pharmaceuticals
- 4.8.6 Genzyme (Sanofi Group)
- 4.8.7 Harvest Technologies (Terumo BCT)
- 4.8.8 Integra LifeSciences
- 4.8.9 Medtronic
- 4.8.10 Musculoskeletal Transplant Foundation (MTF)
- 4.8.11 NuVasive
- 4.8.12 Orthofix
- 4.8.13 RTI Surgical
- 4.8.14 Stryker
- 4.8.15 Vericel Corporation (formerly Aastrom Bioscience)
- 4.8.16 Zimmer Biomet
- 4.9 SWOT ANALYSIS
- 4.9.1 Anika Therapeutics
- 4.9.2 Bioventus
- 4.9.3 DePuy Synthes
- 4.9.4 Ferring Pharmaceuticals
- 4.9.5 Fidia Pharmaceuticals
- 4.9.7 Harvest Technologies (Terumo BCT)
- 4.9.8 Integra LifeSciences
- 4.9.9 Medtronic
- 4.9.10 Musculoskeletal Transplant Foundation (MTF)
- 4.9.11 NuVasive
- 4.9.12 Orthofix
- 4.9.14 Stryker
- 4.9.15 Vericel Corporation (formerly Aastrom Bioscience)
- 4.9.16 Zimmer Biomet
- COUNTRY PROFILES
- 5.1 INTRODUCTION
- 5.1.1 Population
- 5.1.2 GDP Per Capita
- 5.1.3 Price Index
- 5.2 GERMANY
- 5.3 FRANCE
- 5.4 UNITED KINGDOM
- 5.5 ITALY
- 5.6 SPAIN
- 5.7 BENELUX
- 5.8 SCANDINAVIA
- 5.9 AUSTRIA
- 5.10 SWITZERLAND
- 5.11 PORTUGAL
- PROCEDURE NUMBERS
- 6.1 INTRODUCTION
- 6.2 PROCEDURES
- 6.2.1 By Material
- 6.2.2 By Indication
- 6.2.3 Units per Procedure by Indication
- 6.3 GROWTH FACTOR BONE GRAFT PROCEDURE NUMBERS
- 6.4 HYALURONIC ACID TREATMENT NUMBERS BY TYPE
- 6.5 CARTILAGE REPAIR PROCEDURE NUMBERS BY TYPE
- ORTHOPEDIC BONE GRAFT SUBSTITUTE MARKET
- 7.1 INTRODUCTION
- 7.2 MARKET OVERVIEW
- 7.2.1 Orthopedic Bone Graft Substitute Market by Material
- 7.2.2 Orthopedic Bone Graft Substitute Market by Indication
- 7.3 MARKET ANALYSIS AND FORECAST
- 7.3.1 Total Bone Graft Substitute Market
- 7.3.2 Total Allograft Bone Graft Substitute Market
- 7.3.2.1 Total Allograft Spine Market
- 7.3.2.1.1 Allograft Cervical Spine Market
- 7.3.2.1.2 Allograft Thoracolumbar Spine Market
- 7.3.2.2 Allograft Trauma and Reconstruction Market
- 7.3.2.3 Allograft Craniomaxillofacial Market
- 7.3.3 Total Synthetic Bone Graft Substitute Market
- 7.3.3.1 Total Synthetic Spine Market
- 7.3.3.1.1 Synthetic Cervical Spine Market
- 7.3.3.1.2 Synthetic Thoracolumbar Spine Market
- 7.3.3.2 Synthetic Trauma and Reconstruction Market
- 7.3.3.3 Synthetic Craniomaxillofacial Market
- 7.3.4 Total Demineralized Bone Graft Substitute Bone Matrix Market
- 7.3.4.1 Total Demineralized Bone Matrix Spine Market
- 7.3.4.1.1 Demineralized Bone Matrix Cervical Spine Market
- 7.3.4.1.2 Demineralized Bone Matrix Thoracolumbar Spine Market
- 7.3.4.2 Demineralized Bone Matrix Trauma and Reconstruction Market
- 7.3.4.3 Demineralized Bone Matrix Craniomaxillofacial Market
- 7.4 DRIVERS AND LIMITERS
- 7.4.1 Market Drivers
- 7.4.2 Market Limiters
- 7.5 COMPETITIVE MARKET SHARE ANALYSIS
- HYALURONIC ACID VISCOSUPPLEMENTATION MARKET
- 8.1 INTRODUCTION
- 8.1.1 Benefits of Viscosupplementation
- 8.1.2 Synovial Fluid
- 8.1.3 Product Types
- 8.2 MARKET OVERVIEW
- 8.3 MARKET ANALYSIS AND FORECAST
- 8.3.1 Total Hyaluronic Acid Viscosupplementation Market
- 8.3.2 Single-Injection Hyaluronic Acid Viscosupplementation Market
- 8.3.3 Three-Injection Hyaluronic Acid Viscosupplementation Market
- 8.3.4 Five-Injection Hyaluronic Acid Viscosupplementation Market
- 8.4 DRIVERS AND LIMITERS
- 8.4.1 Market Drivers
- 8.4.2 Market Limiters
- 8.5 COMPETITIVE MARKET SHARE ANALYSIS
- BONE MORPHOGENETIC PROTEIN GROWTH FACTOR THERAPY MARKET
- 9.1 INTRODUCTION
- 9.2 MARKET ANALYSIS AND FORECAST
- 9.3 DRIVERS AND LIMITERS
- 9.3.1 Market Drivers
- 9.3.2 Market Limiters
- 9.4 COMPETITIVE MARKET SHARE ANALYSIS
- ORTHOPEDIC CARTILAGE REPAIR MARKET
- 10.1 INTRODUCTION
- 10.1.1 Methods for Cartilage Repair
- 10.1.1.1 Osteochondral Allograft Transfer
- 10.1.1.2 Autologous Chondrocyte Implantation (ACI)
- 10.1.1.3 Meniscal Allograft Transplantation
- 10.2 MARKET OVERVIEW
- 10.3 MARKET ANALYSIS AND FORECAST
- 10.3.1 Osteochondral Allograft Market
- 10.3.2 Meniscal Allograft Market
- 10.3.3 Autologous Chondrocyte Implantation Market
- 10.3.4 Osteochondral Autograft Market
- 10.4 DRIVERS AND LIMITERS
- 10.4.1 Market Drivers
- 10.4.2 Market Limiters
- 10.5 COMPETITIVE MARKET SHARE ANALYSIS
- APPENDIX I: ORTHOPEDIC CELL THERAPY MARKET
- 11.1 INTRODUCTION
- 11.2 CELL THERAPY TREATMENT NUMBERS
- 11.2.1 Overview by Type
- 11.3 MARKET OVERVIEW
- 11.4 MARKET ANALYSIS AND FORECAST
- 11.4.1 Platelet-Rich Plasma Market
- 11.4.2 Bone Marrow Concentrate Market
- 11.5 DRIVERS AND LIMITERS
- 11.5.1 Market Drivers
- 11.5.2 Market Limiters
- 11.6 COMPETITIVE MARKET SHARE ANALYSIS
- APPENDIX II: CELLULAR ALLOGRAFT MARKET
- 12.1 INTRODUCTION
- 12.1.1 Lineage
- 12.1.1.1 Human Embryonic Stem Cells (hESCs)
- 12.1.1.2 Mesenchymal Stem Cells (MSCs)
- 12.1.1.3 Other Therapeutic Applications
- ABBREVIATIONS
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook